CompletedPhase 3NCT05194124
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
Studying Bardet-Biedl syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Rhythm Pharmaceuticals, Inc.
- Principal Investigator
- David Meeker, MDRhythm Pharmaceuticals, Inc.
- Intervention
- Setmelanotide 2 mg(drug)
- Enrollment
- 19 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2021 – 2023
Study locations (7)
- Honor Health Research Institute, Scottsdale, Arizona, United States
- Marshfield Clinic Research Institute, Marshfield, Wisconsin, United States
- Alberta Health Services, Edmonton, Alberta, Canada
- Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany
- Erasmus MC, Rotterdam, Netherlands
- UPR Medical Sciences Campus, Rio Piedras, Puerto Rico
- Addenbrooke's Hospital, Cambridge, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05194124 on ClinicalTrials.govOther trials for Bardet-Biedl syndrome
Additional recruiting or active studies for the same condition.